Moderna Inc

Moderna’s April 8 bullish momentum and upcoming ESCMID data on its mRNA‑1010 influenza vaccine promise to drive pipeline expansion, regulatory gains, and stock upside.

Moderna’s $50.52 stock faces a turning point: leadership changes and EMA’s COVID‑influenza combo endorsement boost momentum, but a negative P/E and high volatility demand careful investor scrutiny.

Moderna’s mCOMBRIAX gets EU approval as the first combined COVID‑flu mRNA shot, promising single‑dose protection and a new revenue stream for the company.

Moderna’s share price plunged 83% from late 2022 to late 2025, ranking among the worst performers in a flat S&P 500 session while precious metals spiked.

Moderna secures CEPI funding for Phase III influenza vaccine, fast‑tracking its mRNA tech and boosting investor hope amid market volatility.

Moderna secures $54.3 million from CEPI to fast‑track its bird‑flu vaccine, advancing Phase III trials and boosting pandemic‑preparedness prospects.

Moderna’s $1.5B credit line and first revenue rise in three years signal a strategic turnaround from its pandemic‑era focus to a diversified, mRNA‑driven growth trajectory.

Moderna Inc.’s stock price has declined significantly from its 52-week high, with a current price of $27.92, and a hypothetical $10,000 investment made in 2020 would have lost 61.75% in value by 2025.

Moderna’s stock plummeted 6.56% to a 6-month low after a report suggested the Trump administration was linking the company’s COVID-19 vaccine to the deaths of 25 children, sparking a wave of negative sentiment in the vaccine-maker sector.

Moderna Inc.’s stock has surged 6.19% to $28.74, marking a significant rebound in the biotech sector, driven by investor confidence in the company’s mRNA technology and future prospects.